VLA1553
Prevention of Chikungunya Virus Infection
Phase 3Under Regulatory Review
Key Facts
Indication
Prevention of Chikungunya Virus Infection
Phase
Phase 3
Status
Under Regulatory Review
Company
About Bavarian Nordic
Bavarian Nordic is a publicly traded vaccine specialist with a firm focus on developing and manufacturing life-saving immunizations. The company has demonstrated strong commercial momentum, particularly in its Travel Health business, and has been a key supplier of a non-replicating smallpox/mpox vaccine for global public health stockpiles. Its strategy leverages a fully integrated model from R&D through manufacturing to address infectious disease threats.
View full company profileTherapeutic Areas
Other Prevention of Chikungunya Virus Infection Drugs
| Drug | Company | Phase |
|---|---|---|
| CHIKV VLP Vaccine | Emergent BioSolutions | Phase 3 |